NCT03709576 - Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Pevonedistat

To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.

PROCEDURE

transplant

Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.

DRUG

Azacitidine

To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.

Trial Locations (1)

17033

Penn State Hershey Medical Center: Penn State Cancer Institute, Hershey